Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials

Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

(2016) Sara Heebøll et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

(2015) Forouzan Faghihzadeh et al.   BRITISH JOURNAL OF NUTRITION

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial

(2015) Shihui Chen et al.   DIGESTIVE AND LIVER DISEASE

Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease

(2015) Long-Xin Qiu   WORLD JOURNAL OF GASTROENTEROLOGY

Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease

(2014) Veronique S. Chachay et al.   Clinical Gastroenterology and Hepatology

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

(2014) Forouzan Faghihzadeh et al.   NUTRITION RESEARCH

Weight Loss in Nonalcoholic Fatty Liver Disease Patients in an Ambulatory Care Setting Is Largely Unsuccessful but Correlates with Frequency of Clinic Visits

(2014) Anwar Dudekula et al.   PLoS One

Anti-Inflammatory and Antioxidant Effects of Resveratrol in Healthy Smokers A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial

(2013) S. Bo et al.   CURRENT MEDICINAL CHEMISTRY

Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD

(2013) Amedeo Lonardo et al.   CURRENT PHARMACEUTICAL DESIGN

Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease

(2013) Lake Li et al.   FOOD AND CHEMICAL TOXICOLOGY

Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway

(2013) Zhong Q. Wang et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The global NAFLD epidemic

(2013) Rohit Loomba et al.   Nature Reviews Gastroenterology & Hepatology

Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation

(2013) João Marcus Oliveira Andrade et al.   NUTRITION

Finding a Target for Resveratrol

(2012) Ruth I. Tennen et al.   CELL

High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition

(2012) M. M. Poulsen et al.   DIABETES

Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis

(2012) Federico Salamone et al.   Translational Research

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

(2011) G. Vernon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats

(2011) Roberta Schmatz et al.   BIOCHIMIE

Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis

(2011) Federico Salamone et al.   DIGESTIVE AND LIVER DISEASE

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY

AMP-Activated Protein Kinase-Deficient Mice Are Resistant to the Metabolic Effects of Resveratrol

(2009) J.-H. Um et al.   DIABETES

Mukitake mushroom (Panellus serotinus) alleviates nonalcoholic fatty liver disease through the suppression of monocyte chemoattractant protein 1 production in db/db mice

(2009) Koji Nagao et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE